title: [Tthe efficacy and safety of drug therapy divaza in patients with chronic cerebral ischemia].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of divazа in the treatment of cognitive and emotional disorders in patients with chronic cerebral ischemia (CCI) based on clinical findings and laboratory markers of endothelial dysfunction.
  
  
  METHODS
  Thirty patients with CCI, aged 40 to 70 years, were examined. All patients were treated with divazа (2 tablets 3 times a day) for 12 weeks. Cognitive functions and markers of endothelial dysfunction (the activity of endothelial NO-synthase (eNOS), the number of circulating desquamated endothelial cells in blood plasma) were measured at baseline and after treatment.
  
  
  RESULTS
  Divazа significantly reduced the severity of clinical symptoms and had a positive effect on endothelial dysfunction normalizing the tone of cerebral vessels and preventing deendotheliazation.
  
  
  CONCLUSIONS
  The use of divazа resulted in clinical improvement and normalization of markers of endothelial dysfunction as well.
authors.affiliation: Sechenov First Мoscow State Medical University, Moscow, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Fateeva
authors.affiliation: Altai State Medical University, Barnaul, Russia.
authors.forename: G I
authors.initials: GI
authors.lastname: Shumakher
authors.affiliation: Barnaul Multidisciplinary Medical Center 'Isida', Barnaul, Russia.
authors.forename: E N
authors.initials: EN
authors.lastname: Vorob'eva
authors.affiliation: Altai State Medical University, Barnaul, Russia.
authors.forename: M A
authors.initials: MA
authors.lastname: Khoreva
authors.affiliation: Altai State Medical University, Barnaul, Russia.
authors.forename: L R
authors.initials: LR
authors.lastname: Voskanyan
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001921:Brain / Q000098:blood supply; D002545:Brain Ischemia / Q000150:complications / Q000523:psychology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy* / Q000209:etiology*; D052250:Nitric Oxide Synthase Type III / Q000032:analysis / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D015415:Biomarkers; C000610361:divaza; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III